145 related articles for article (PubMed ID: 38669474)
1. Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone.
Wright EE; Roberts GJ; Chuang JS; Nabutovsky Y; Virdi N; Miller E
Diabetes Technol Ther; 2024 May; ():. PubMed ID: 38669474
[No Abstract] [Full Text] [Related]
2. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
[TBL] [Abstract][Full Text] [Related]
3. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of the FreeStyle Libre
Jendle J; Eeg-Olofsson K; Svensson AM; Franzen S; Lamotte M; Levrat-Guillen F
Diabetes Ther; 2021 Dec; 12(12):3137-3152. PubMed ID: 34694584
[TBL] [Abstract][Full Text] [Related]
5. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
[TBL] [Abstract][Full Text] [Related]
6. Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin.
Chou HW; Cheng KP; Lin AC; Hung HC; Lin CH; Wang CC; Wu HT; Ou HY
Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36559020
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
[TBL] [Abstract][Full Text] [Related]
8. Is insulin the preferred treatment for HbA1c >9%?
Bloomgarden Z
J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
[TBL] [Abstract][Full Text] [Related]
9. Determinants of HbA1c reduction with FreeStyle Libre flash glucose monitoring (FLARE-NL 5).
Lameijer A; Fokkert MJ; Edens MA; Slingerland RJ; Bilo HJG; van Dijk PR
J Clin Transl Endocrinol; 2020 Dec; 22():100237. PubMed ID: 33102135
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry.
Jung H; Tittel SR; Schloot NC; Heitmann E; Otto T; Lebrec J; Pavel M; Lanzinger S
Diabetes Obes Metab; 2023 Jul; 25(7):1813-1822. PubMed ID: 36855221
[TBL] [Abstract][Full Text] [Related]
11. Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).
Polonsky WH; Arora R; Faurby M; Fernandes J; Liebl A
Diabetes Ther; 2022 Jan; 13(1):175-187. PubMed ID: 34918213
[TBL] [Abstract][Full Text] [Related]
12. Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study.
Peng XV; McCrimmon RJ; Shepherd L; Boss A; Lubwama R; Dex T; Skolnik N; Ji L; Avogaro A; Blonde L
Diabetes Ther; 2020 Nov; 11(11):2629-2645. PubMed ID: 32902774
[TBL] [Abstract][Full Text] [Related]
13. Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin.
Blonde L; Raccah D; Lew E; Meyers J; Nikonova E; Ajmera M; Davis KL; Bertolini M; Guerci B
Diabetes Ther; 2018 Jun; 9(3):1169-1184. PubMed ID: 29675797
[TBL] [Abstract][Full Text] [Related]
14. Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study.
Hoog M; Paczkowski R; Huang A; Halpern R; Buysman E; Stackland S; Zhang Y; Wangia-Dixon R
Diabetes Ther; 2023 Nov; 14(11):1947-1958. PubMed ID: 37740872
[TBL] [Abstract][Full Text] [Related]
15. Use of flash glucose-sensing technology (FreeStyle Libre) in youth with type 1 diabetes: AWeSoMe study group real-life observational experience.
Landau Z; Abiri S; Gruber N; Levy-Shraga Y; Brener A; Lebenthal Y; Barash G; Pinhas-Hamiel O; Rachmiel M
Acta Diabetol; 2018 Dec; 55(12):1303-1310. PubMed ID: 30171412
[TBL] [Abstract][Full Text] [Related]
16. Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study.
Peng XV; Ayyagari R; Lubwama R; Shi L; Price-Haywood EG; Hollander P; Fonseca V
Diabetes Ther; 2020 Apr; 11(4):995-1005. PubMed ID: 32112204
[TBL] [Abstract][Full Text] [Related]
17. The use of flash glucose monitoring significantly improves glycemic control in type 2 diabetes managed with basal bolus insulin therapy compared to self-monitoring of blood glucose: A prospective observational cohort study.
Bosi E; Gregori G; Cruciani C; Irace C; Pozzilli P; Buzzetti R
Diabetes Res Clin Pract; 2022 Jan; 183():109172. PubMed ID: 34883185
[TBL] [Abstract][Full Text] [Related]
18. Reduced Rate of Hospitalizations for Acute Diabetes Events Before and After FreeStyle Libre
Riveline JP; Levrat-Guillen F; Detournay B; Vicaut E; De Pouvourville G; Emery C; Guerci B
Diabetes Technol Ther; 2024 Jul; ():. PubMed ID: 38885325
[No Abstract] [Full Text] [Related]
19. Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study.
Hoog M; Maldonado JM; Wangia-Dixon R; Halpern R; Buysman E; Gremel GW; Huang A; Konig M
Diabetes Ther; 2024 Apr; 15(4):855-867. PubMed ID: 38427164
[TBL] [Abstract][Full Text] [Related]
20. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.
Edelman S; Cassarino D; Kayne D; Dex T; Li X; Pasquel FJ
J Manag Care Spec Pharm; 2022 Sep; 28(9):958-968. PubMed ID: 36001104
[No Abstract] [Full Text] [Related]
[Next] [New Search]
